Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus paclitaxel, carboplatin, and bevacizumab in newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer
2016-003472-52Phase 3Completed
- Sponsor
- Roche
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Atezolizumab arm with Placebo arm (2 arms). Primary endpoint: Investigator-assessed progression-free survival. Started May 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2016-003472-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003472-52.